Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials.
Merola JF, Gottlieb AB, Pinter A, Elewski B, Gooderham M, Warren RB, Piaserico S, Wixted K, Cross N, Tilt N, Wiegratz S, Mrowietz U. Merola JF, et al. Among authors: piaserico s. Dermatol Ther (Heidelb). 2024 Dec;14(12):3291-3306. doi: 10.1007/s13555-024-01295-w. Epub 2024 Nov 22. Dermatol Ther (Heidelb). 2024. PMID: 39578348 Free PMC article.
A new instrument for the screening of psoriatic arthritis among psoriatic patients.
De Marco G, Marchesoni A, Manara M, Gisondi P, Idolazzi L, Ramonda R, Piaserico S, Cauli A, Cimmino MA, Tomatis V, Salvarani C, Scrivo R, Zanetti A, Carrara G, Scirè CA, Cattaneo A. De Marco G, et al. Among authors: piaserico s. Clin Exp Rheumatol. 2024 Oct 25. doi: 10.55563/clinexprheumatol/ug6vti. Online ahead of print. Clin Exp Rheumatol. 2024. PMID: 39480505
Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World Evidence.
Malagoli P, Dapavo P, Amerio P, Atzori L, Balato A, Bardazzi F, Bianchi L, Cattaneo A, Chiricozzi A, Congedo M, Fargnoli MC, Giofrè C, Gisondi P, Guarneri C, Lembo S, Loconsole F, Mazzocchetti G, Mercuri SR, Morrone P, Offidani AM, Palazzo G, Parodi A, Pellacani G, Piaserico S, Potenza C, Prignano F, Romanelli M, Savoia P, Stingeni L, Travaglini M, Trovato E, Venturini M, Zichichi L, Costanzo A. Malagoli P, et al. Among authors: piaserico s. Dermatol Ther (Heidelb). 2024 Oct;14(10):2739-2757. doi: 10.1007/s13555-024-01255-4. Epub 2024 Sep 24. Dermatol Ther (Heidelb). 2024. PMID: 39316358 Free PMC article. Review.
Identifying Predictors of PASI100 Responses up to Month 12 in Patients with Moderate-to-severe Psoriasis Receiving Biologics in the Psoriasis Study of Health Outcomes (PSoHO).
Armstrong AW, Riedl E, Brunner PM, Piaserico S, Visser WI, Haustrup N, Konicek BW, Kadziola Z, Nunez M, Brnabic A, Schuster C. Armstrong AW, et al. Among authors: piaserico s. Acta Derm Venereol. 2024 Sep 5;104:adv40556. doi: 10.2340/actadv.v104.40556. Acta Derm Venereol. 2024. PMID: 39235051 Free PMC article.
Early intervention and cumulative life course impairment in psoriasis: a review.
Arancio LMH, D'Amico D, Dastoli S, Fiorella CS, Manfredini M, Moretta G, Paolino G, Levi A, Di Fino S, Zucchi B, Piaserico S. Arancio LMH, et al. Among authors: piaserico s. Clin Exp Dermatol. 2024 Nov 22;49(12):1525-1531. doi: 10.1093/ced/llae282. Clin Exp Dermatol. 2024. PMID: 39045914 Review.
Effectiveness of guselkumab in patients with facial and/or genital psoriasis: Interim analysis results at Week 12 from the GULLIVER study.
Bonifati C, Lembo S, Richetta AG, Romanelli M, Satolli F, Corazza M, Atzori L, Lasagni C, Potenza C, Savoia P, Bardazzi F, Di Lernia VG, Bianchi L, Fabbrocini G, Giofrè C, Zichichi L, Guarneri C, Pallotta S, Fargnoli MC, Loconsole F, Offidani A, Burlando M, Piaserico S, Peris K, Papini M, Carrera CG, Costanzo A, Prignano F, Bongiorno R, Dapavo P, Stingeni L, Donini M, Micali G, Rongioletti F, Stinco G, Gramiccia T, Cantini G, Argenziano G. Bonifati C, et al. Among authors: piaserico s. J Eur Acad Dermatol Venereol. 2024 Jun 26. doi: 10.1111/jdv.20187. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 38924150
Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort study.
Chiricozzi A, Coscarella G, Puig L, Vender R, Yeung J, Carrascosa JM, Piaserico S, Gisondi P, Lynde C, Ferreira P, Bastos PM, Dauden E, Leite L, Valerio J, Del Alcázar-Viladomiu E, Vilarrasa E, Llamas-Velasco M, Alessandri-Bonetti M, Messina F, Bruni M, Di Brizzi EV, Ricceri F, Nidegger A, Hugo J, Mufti A, Daponte AI, Teixeira L, Balato A, Romanelli M, Prignano F, Gkalpakiotis S, Conrad C, Lazaridou E, Rompoti N, Stratigos AJ, Nogueira M, Peris K, Torres T. Chiricozzi A, et al. Among authors: piaserico s. J Eur Acad Dermatol Venereol. 2024 Nov;38(11):2175-2185. doi: 10.1111/jdv.20143. Epub 2024 Jun 11. J Eur Acad Dermatol Venereol. 2024. PMID: 38860729
OPT-In; Optimized Patient Treatment Outcomes in Plaque Psoriasis: A 3-Year State-Transition Treatment-Sequencing Model in the Italian Setting.
Alulis S, Bernardini N, Burlando M, Costanzo A, Francesa Morel PC, Gisondi P, Loconsole F, Megna M, Pellacani G, Piaserico S, Prignano F, Secchi O, Skroza N, Hassan F. Alulis S, et al. Among authors: piaserico s. Dermatol Ther (Heidelb). 2024 May;14(5):1273-1291. doi: 10.1007/s13555-024-01170-8. Epub 2024 May 10. Dermatol Ther (Heidelb). 2024. PMID: 38727995 Free PMC article.
216 results